Immunotherapeutic concepts including immune checkpoint inhibitors (ICIs) of cytotoxic T-lymphocytes-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) have dramatically changed clinical practice in cancer treatment. The gene discussed is PDCD1; the disease is cancer.